Actively Recruiting
Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
Led by Xuesong Li · Updated on 2023-11-07
90
Participants Needed
2
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this study, we propose to conduct an ambispective study to analyze the safety of preserved renal unit surgery combined with postoperative adjuvant radiotherapy in patients with limited stage ureteral cancer with high risk factors, and the efficacy analysis compared with traditional radical surgery. It is hoped that a treatment method that preserves patients' renal function to improve the tolerance of subsequent drug therapy without decreasing the effect of tumor treatment can be achieved in patients with high-risk factors.
CONDITIONS
Official Title
Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ureteral cancer patients with high-risk factors (multifocal; G3; T2-4)
- Surgery candidates for partial terminal ureteral resection or radical nephroureterectomy
- Age 18 years or older
- Completion of abdominopelvic CT within 4 weeks before enrollment to exclude distant and lymph node metastasis
- No other malignant neoplastic diseases in the last 5 years except non-melanoma skin cancer and ductal carcinoma in situ of the breast
- Willingness to participate in necessary examinations, follow-up, and provide written informed consent
You will not qualify if you...
- Presence of distant metastasis or retroperitoneal lymph node metastasis detected at surgery
- R2 resection patients
- History of bladder cancer
- History of pelvic or abdominal radiotherapy
- History of inflammatory bowel disease
- History of systemic chemotherapy
- Pregnant or breastfeeding women, or women of childbearing potential not using reliable contraception
- Active infections in patients with bleeding disorders
- Clinically significant cardiac disease (e.g., hypertension requiring medication, unstable angina, NYHA class 62II congestive heart failure, unstable arrhythmias, or class 62II peripheral vascular disease)
- Psychological, family, or social factors preventing informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Departmeng of Urology, Peking University First Hospital
Beijing, China
Actively Recruiting
2
Department of Radiotherapy Oncology, Peking University First Hospital
Beijing, China
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here